

Supplementary Data:

Delivery of Mitogen-Activated Protein Kinase Inhibitor for Hepatocellular Carcinoma Stem Cell Therapy

Yang Liu^a, Xin Wang^a, Chun-Yang Sun^a, Jun Wang^{a,b,c,}*

^aThe CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science & Technology of China, Hefei, Anhui 230027, China

^bHefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China;

^cHigh Magnetic Field Laboratory of CAS, University of Science and Technology of China, Hefei, Anhui 230026, China

*Corresponding author: Prof. Jun Wang, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, P.R. China, Tel.: +86 551 63600335, Fax: +86 551 63600402, E-mail: jwang699@ustc.edu.cn



A**B**

Figure S1. Cytotoxicity of free nanoparticles at concentration from 1 mg/mL to 1/24 mg/mL to HepG2, Hep3B, SMMC-7721 adherent (A) and mammosphere (B) cells.

Data are shown as means \pm s.d. (n=6).




Figure S2. Examination of mouse ALT, AST and LDH levels in the serum HepG2 xenograft-bearing mice after the last day of treatment. The data are shown as mean \pm SD (n = 5). **P<0.01, ***P<0.001, free U0126 compared to PBS at each group.